Immunological Medicine最新文献

Macrophage activation syndrome associated with multi-system inflammatory syndrome in children: a case report and cytokine profile. 儿童巨噬细胞激活综合征与多系统炎症综合征相关：病例报告和细胞因子分析

IF 2.9

Immunological Medicine Pub Date : 2025-09-13 DOI: 10.1080/25785826.2025.2559458

Yuji Fujita, Masaki Shimizu, Sayaka Aihara, Kohei Nomura, Shinya Yoshihara, Kaori Sekine, Maho Hatano, Shuya Kaneko, Hideaki Shiraishi

{"title":"Macrophage activation syndrome associated with multi-system inflammatory syndrome in children: a case report and cytokine profile.","authors":"Yuji Fujita, Masaki Shimizu, Sayaka Aihara, Kohei Nomura, Shinya Yoshihara, Kaori Sekine, Maho Hatano, Shuya Kaneko, Hideaki Shiraishi","doi":"10.1080/25785826.2025.2559458","DOIUrl":"https://doi.org/10.1080/25785826.2025.2559458","url":null,"abstract":"Macrophage activation syndrome (MAS) is a potentially life-threatening complication requiring early diagnosis and prompt treatment in rheumatic diseases such as systemic juvenile idiopathic arthritis (sJIA). Recently, multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was reported to be complicated by MAS. The diagnostic criteria for MAS-associated MIS-C (MIS-C/MAS) remain unknown. We report the case of a 12-year-old boy who presented with fever for 4 days, swollen cervical lymph nodes, conjunctival congestion, red lips, strawberry tongue, irregular erythematous lesions, abdominal pain, and diarrhoea; he had coronavirus disease 2019 (COVID-19) 1 month prior. The patient was diagnosed MIS-C/MAS based on the criteria for sJIA/MAS, treated with intravenous immunoglobulin, glucocorticoids, and cyclosporine without any coronary artery sequelae. Evaluation of the patient's serum cytokine profile revealed that CXCL9 level (14259 pg/mL, reference range <31-83 pg/mL) was significantly elevated, as in sJIA/MAS. Based on cytokine profiles, the diagnostic criteria for MIC-S/MAS may be consistent with those for sJIA/MAS. No previous studies have reported on the cytokine profiles of MIS-C/MAS. Pediatricians should consider that MIS-C may complicate MAS, such as sJIA. Glucocorticoids and cyclosporine may be considered in cases of MIS-C complicated by MAS.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-5"},"PeriodicalIF":2.9,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145055876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of drug retention rates between TNF inhibitors and tocilizumab for Takayasu arteritis: a multicenter retrospective study. 肿瘤坏死因子抑制剂和托珠单抗治疗高须动脉炎的药物保留率比较：一项多中心回顾性研究。

IF 2.9

Immunological Medicine Pub Date : 2025-09-11 DOI: 10.1080/25785826.2025.2557038

Takahiro Sugiyama, Shunsuke Furuta, Taro Iwamoto, Kei Ikeda, Shin-Ichiro Kagami, Yasuhiko Kita, Kazuhiro Kurasawa, Shigekazu Takahashi, Daiki Nakagomi, Masaki Hiraguri, Hiroshi Nakajima

{"title":"Comparison of drug retention rates between TNF inhibitors and tocilizumab for Takayasu arteritis: a multicenter retrospective study.","authors":"Takahiro Sugiyama, Shunsuke Furuta, Taro Iwamoto, Kei Ikeda, Shin-Ichiro Kagami, Yasuhiko Kita, Kazuhiro Kurasawa, Shigekazu Takahashi, Daiki Nakagomi, Masaki Hiraguri, Hiroshi Nakajima","doi":"10.1080/25785826.2025.2557038","DOIUrl":"https://doi.org/10.1080/25785826.2025.2557038","url":null,"abstract":"Objective: We compared the drug retention rate of tumor necrosis factor (TNF) inhibitors (TNFi) and tocilizumab in Takayasu arteritis (TAK) as an index of balance between effectiveness and safety in a real-world setting.Method: We included 50 TAK patients who received biologics in nine hospitals. All patients fulfilled the 1990 American College of Rheumatology classification criteria for TAK. We retrospectively collected clinical information. We analyzed the drug retention rates and the reasons for discontinuation regarding TNFi and tocilizumab.Results: The prednisolone dose at the start of the first biologics was a median of 15 mg/day, and an immunosuppressant was used in 25 patients. Tocilizumab was the most frequent first biologics (64%). Twenty-seven of 32 patients continued on tocilizumab, and four of 18 patients continued on TNFi. The retention rate was significantly higher in tocilizumab than in TNFi (87.9% vs. 66.7% at one year, p = 0.024). The reasons for discontinuing tocilizumab were primary failure in two patients, and other reasons in three. The reasons for discontinuing TNFi were secondary failure in five patients, primary failure in four patients, and other reasons in five.Conclusion: Tocilizumab has a higher continuation rate than TNFi, suggesting that tocilizumab may have better benefit-risk balance for TAK patients.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical profile of IgG4-related disease in Japan based on the rare disease data registry. 基于罕见病数据登记的日本 IgG4 相关疾病临床概况。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-11-28 DOI: 10.1080/25785826.2024.2430812

Motohisa Yamamoto, Masatoshi Kanda, Ichiro Mizushima, Atsushi Kanno, Takeji Umemura, Tsukasa Ikeura, Yuzo Kodama, Hiroaki Dobashi, Yoshiya Tanaka, Atsushi Masamune, Masafumi Moriyama, Takako Saeki, Shoko Matsui, Tomoki Origuchi, Yasufumi Masaki, Masanori Asada, Hisanori Umehara, Hiroshi Seno, Itaru Naitoh, Satoshi Yamamoto, Eisuke Iwasaki, Kensuke Kubota, Shiroh Tanoue, Takayoshi Nishino, Hiroto Tsuboi, Yasushi Matsumoto, Hiroyuki Isayama, Hiroshi Goto, Kenji Notohara, Kazushige Uchida, Ken Kawabe, Kazunori Yamada, Satomi Kasashima, Masayuki Takahira, Yasuharu Sato, Izumi Kawachi, Izumi Yamaguchi, Kazuichi Okazaki, Seiji Nakamura, Fumihiko Matsuda, Hideki Ishikawa, Mitsuhiro Kawano

{"title":"Clinical profile of IgG4-related disease in Japan based on the rare disease data registry.","authors":"Motohisa Yamamoto, Masatoshi Kanda, Ichiro Mizushima, Atsushi Kanno, Takeji Umemura, Tsukasa Ikeura, Yuzo Kodama, Hiroaki Dobashi, Yoshiya Tanaka, Atsushi Masamune, Masafumi Moriyama, Takako Saeki, Shoko Matsui, Tomoki Origuchi, Yasufumi Masaki, Masanori Asada, Hisanori Umehara, Hiroshi Seno, Itaru Naitoh, Satoshi Yamamoto, Eisuke Iwasaki, Kensuke Kubota, Shiroh Tanoue, Takayoshi Nishino, Hiroto Tsuboi, Yasushi Matsumoto, Hiroyuki Isayama, Hiroshi Goto, Kenji Notohara, Kazushige Uchida, Ken Kawabe, Kazunori Yamada, Satomi Kasashima, Masayuki Takahira, Yasuharu Sato, Izumi Kawachi, Izumi Yamaguchi, Kazuichi Okazaki, Seiji Nakamura, Fumihiko Matsuda, Hideki Ishikawa, Mitsuhiro Kawano","doi":"10.1080/25785826.2024.2430812","DOIUrl":"10.1080/25785826.2024.2430812","url":null,"abstract":"We started a registry for cases of immunoglobulin (Ig)G4-related disease (IgG4-RD) in December 2019 to clarify the clinical profile of IgG4-RD. In this study, clinical information from 854 cases registered by February 16, 2024 was analyzed from multiple perspectives. Diagnosis of IgG4-RD was made in 808 cases, comprising 638 definite, 38 probable, and 132 possible. The mean ± SD age at time of enrollment of the 808 cases was 67.9 ± 11.3 years, with 68.8% being male. The pancreas was the most frequently affected organ (49.8%), followed by the submandibular glands (46.2%) and lacrimal glands (30.6%). This study reconfirmed the pancreas and head-and-neck region as major affected areas in IgG4-RD. Clinically, submandibular adenitis and autoimmune pancreatitis often occur together in the same patient, but no association between the two organs was observed in our analysis. Regarding diagnosis, the comprehensive diagnostic criteria were most commonly used (63.6%). Storiform fibrosis and phlebitis obliterans were detected at different frequencies in different organs. In summary, this registry study identified clinical, imaging, hematologic, and pathologic findings in 808 Japanese patients with IgG4-RD. The frequency of affected organs and their characteristic pathological findings will be particularly useful for future practice.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"192-202"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expansion of granulocyte-macrophage colony-stimulating factor producing CD4+ T cells in an animal model with enhanced interleukin-1 signal. 在白细胞介素-1 信号增强的动物模型中扩增产生粒细胞-巨噬细胞集落刺激因子的 CD4+ T 细胞。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-11-26 DOI: 10.1080/25785826.2024.2430913

Sho Ishigaki, Keiko Yoshimoto, Mitsuhiro Akiyama, Kotaro Matsumoto, Katsuya Suzuki, Kazuhiro Yamanoi, Yoichiro Iwakura, Tsutomu Takeuchi, Yuko Kaneko

{"title":"Expansion of granulocyte-macrophage colony-stimulating factor producing CD4+ T cells in an animal model with enhanced interleukin-1 signal.","authors":"Sho Ishigaki, Keiko Yoshimoto, Mitsuhiro Akiyama, Kotaro Matsumoto, Katsuya Suzuki, Kazuhiro Yamanoi, Yoichiro Iwakura, Tsutomu Takeuchi, Yuko Kaneko","doi":"10.1080/25785826.2024.2430913","DOIUrl":"10.1080/25785826.2024.2430913","url":null,"abstract":"Interleukin-1, a pro-inflammatory cytokine, plays a crucial role in inflammatory disease pathogenesis. Interleukin-1 receptor antagonist knockout (IL-1Ra KO) mice spontaneously develop aortitis, arthritis and dermatitis, and are employed as a model for human inflammatory diseases. Previous studies have shown that transferring total T cells from IL-1Ra KO mice into nude mice induces aortitis and arthritis; however, the roles of specific T cell subsets in these inflammatory responses remain unclear. In this study, we aimed to investigate the T cell subsets in IL-1Ra KO mice. We found that the proportion of PD-1+CD44+CD62L-CD4+ T cells in the spleen and lymph nodes of IL-1Ra KO mice was significantly higher than that of wild type mice. RNA sequencing revealed elevated expression of basic helix-loop-helix family member e40 and granulocyte macrophage colony stimulating factor (GM-CSF) in splenic CD44+CD62L-CD4+ T cells from IL-1Ra KO mice. In addition, GM-CSF production from splenic CD4+ T cells of IL-1Ra KO mice was significantly higher than that of wild type mice when stimulated with PMA and ionomycin in vitro. Notably, immunohistochemical staining showed infiltration of GM-CSF+CD4+ T cells at inflammatory sites in IL-1Ra KO mice. Our results suggest that a subset of GM-CSF+CD4 + T cells emerges under IL-1 signal-enhanced inflammatory conditions.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"183-191"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging roles of checkpoint molecules on B cells. 检查点分子在B细胞中的新作用。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-01-17 DOI: 10.1080/25785826.2025.2454045

Hiromitsu Asashima, Satoshi Akao, Isao Matsumoto

引用次数: 0

Therapeutic potential of trained immunity for malignant disease. 训练免疫对恶性疾病的治疗潜力。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-12-05 DOI: 10.1080/25785826.2024.2438426

Hiroyuki Takahashi, Daibo Kojima, Masato Watanabe

{"title":"Therapeutic potential of trained immunity for malignant disease.","authors":"Hiroyuki Takahashi, Daibo Kojima, Masato Watanabe","doi":"10.1080/25785826.2024.2438426","DOIUrl":"10.1080/25785826.2024.2438426","url":null,"abstract":"Trained immunity (TI) is functional memory displayed by innate immune cells (IICs). TI facilitates rapid, non-specific responses to pathogens upon secondary challenge. It is driven by immunological signaling and metabolic rewriting via epigenetic alteration, triggered by recognition of certain stimuli. Recently, immune checkpoint inhibitors have come into common use in clinical oncology settings, and genetically engineered cytotoxic T cells comprise a potent cancer treatment strategy. However, the contributions of TI in the tumor microenvironment (TME) are only beginning to be uncovered. Accumulating evidence that various microorganisms and vaccines convey tumoricidal ability suggest that TI may become a useful anti-cancer tool. The expected roles of TI in tumor therapy are the 1) promotion of proinflammatory cytokine section, 2) enhancement of phagocytosis, 3) quick expansion and recruitment of cancer-specific cytotoxic T cells to the TME through neoantigen presentation, 4) reversal of immunosuppression in the TME, and 5) removal of pathogens associated with carcinogenesis or tumor development. Medium- to long-term TI durability may reduce the risk of tumor development. Recent findings on TI usher in new aspirations for cancer treatment.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"149-160"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of TRECs/KRECs as immune indicators that reflect immunophenotypes and predict the risk of infection in systemic autoimmune diseases. TRECs/KRECs作为反映免疫表型和预测全身自身免疫性疾病感染风险的免疫指标的作用

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-02-03 DOI: 10.1080/25785826.2025.2460275

Takuji Itakura, Hirokazu Sasaki, Tadashi Hosoya, Natsuka Umezawa, Tetsuya Saito, Hideyuki Iwai, Hisanori Hasegawa, Hiroyuki Sato, Akihiro Hirakawa, Kohsuke Imai, Tomohiro Morio, Naoki Kimura, Shinsuke Yasuda

{"title":"The role of TRECs/KRECs as immune indicators that reflect immunophenotypes and predict the risk of infection in systemic autoimmune diseases.","authors":"Takuji Itakura, Hirokazu Sasaki, Tadashi Hosoya, Natsuka Umezawa, Tetsuya Saito, Hideyuki Iwai, Hisanori Hasegawa, Hiroyuki Sato, Akihiro Hirakawa, Kohsuke Imai, Tomohiro Morio, Naoki Kimura, Shinsuke Yasuda","doi":"10.1080/25785826.2025.2460275","DOIUrl":"10.1080/25785826.2025.2460275","url":null,"abstract":"T cell receptor rearrangement excision circles (TRECs) and immunoglobulin κ-deleting recombination excision circles (KRECs) represent the lymphopoiesis capacity, widely used for newborn screening of inborn errors of immunity. To clarify the significance of TRECs and KRECs as immune indicators in patients with systemic autoimmune diseases, we prospectively evaluated TREC and KREC levels with qPCR, lymphocyte phenotypes with flow cytometry, along with lymphocyte counts and serum immunoglobulin levels in peripheral blood samples from newly diagnosed patients. Each variable was assessed before immunosuppressive treatments (baseline), 3-, 6-, and 12-months after the treatment. Severe infections were recorded until 6 months after treatment. Among 35 patients, TREC and KREC levels were associated positively with the proportion of recent thymic emigrants, naïve T and B cells at all the timepoints. TREC and KREC levels decreased after treatment. The ratios of TREC and KREC levels under treatment to baseline were significantly lower in patients with severe infection than those without. In conclusion, TREC and KREC levels reflect peripheral blood immunophenotypes, specifically recent-emigrated T and B cells, in patients under treatment-naïve and immunosuppressive conditions. The longitudinal changes in TREC and KREC levels were beneficial markers for predicting the risk of severe infection during immunosuppressive treatments.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"233-244"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy. 贝利姆单抗在系统性红斑狼疮慢性期的额外益处和他克莫司联合治疗的疗效。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-12-27 DOI: 10.1080/25785826.2024.2447629

Satoshi Suzuki, Tomoya Otani, Keigo Ikeda, Naoto Tamura, Shinji Morimoto

{"title":"Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy.","authors":"Satoshi Suzuki, Tomoya Otani, Keigo Ikeda, Naoto Tamura, Shinji Morimoto","doi":"10.1080/25785826.2024.2447629","DOIUrl":"10.1080/25785826.2024.2447629","url":null,"abstract":"Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction. The efficacy of tacrolimus and mycophenolate mofetil in combination with belimumab was also compared. In the stable chronic phase, the combination with belimumab improved the SLE Disease Activity Index and reduced glucocorticoid requirement. The tacrolimus with belimumab group was not significantly inferior to the mycophenolate mofetil with belimumab group and was effective in treatment and glucocorticoid sparing including cases at all phases of SLE. To improve the long-term prognosis of SLE, it is crucial to introduce highly selective biological agents and reduce glucocorticoids whenever possible. Belimumab is effective with or without hydroxychloroquine and Tac was effective as concomitant drugs.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"219-225"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristic TARC/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis. IgG4 相关疾病唾液腺中 TARC/CCL17 的特征性表达：潜在的诊断作用和对发病机制的见解。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-02-04 DOI: 10.1080/25785826.2025.2460910

Nanako Kikuchi, Sae Hatanaka, Terufumi Kubo, Ryuta Kamekura, Masatoshi Kanda, Takuya Kakuki, Takashi Sasaya, Kengo Mita, Hiroki Kobayashi, Hajime Ikai, Kenta Sasaki, Naoki Shijubou, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Tadashi Hasegawa, Akihiro Miyazaki, Hiroki Takahashi, Ken-Ichi Takano, Toshihiko Torigoe

{"title":"Characteristic TARC/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis.","authors":"Nanako Kikuchi, Sae Hatanaka, Terufumi Kubo, Ryuta Kamekura, Masatoshi Kanda, Takuya Kakuki, Takashi Sasaya, Kengo Mita, Hiroki Kobayashi, Hajime Ikai, Kenta Sasaki, Naoki Shijubou, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Tadashi Hasegawa, Akihiro Miyazaki, Hiroki Takahashi, Ken-Ichi Takano, Toshihiko Torigoe","doi":"10.1080/25785826.2025.2460910","DOIUrl":"10.1080/25785826.2025.2460910","url":null,"abstract":"Immunoglobulin G4-related disease (IgG4-RD) is a chronic inflammatory condition of unknown etiology characterized by lymphocytic infiltration, fibrosis, and infiltration of IgG4-positive plasma cells. It affects various organs, including the pancreas and salivary glands. Immunological abnormalities are suspected to play a role in its pathogenesis, and there is an epidemiological link to allergic conditions and type 2 inflammation. This study focused on the expression of thymus and activation-regulated chemokine (TARC)/CCL17, which is involved in the migration of T helper 2 and/or regulatory T cells, in salivary gland tissues of patients with IgG4-RD. We analyzed 60 salivary gland biopsy samples obtained from patients at Sapporo Medical University Hospital between 2015 and 2020. Immunohistochemical analysis revealed TARC/CCL17 positivity in 87.2% of histologically confirmed IgG4-RD cases and negativity in 84.6% of histologically unconfirmed but clinically suspected IgG4-RD cases. There was a significant correlation between histologically confirmed IgG4-RD and TARC/CCL17 expression, suggesting its potential diagnostic utility and possible involvement in the pathogenesis of IgG4-RD.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"226-232"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study. 日本不同利妥昔单抗方案治疗抗中性粒细胞细胞质抗体相关血管炎的缓解维持率和安全性：J-CANVAS研究

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-01-11 DOI: 10.1080/25785826.2024.2448912

Chie Ogita, Kazuteru Noguchi, Jiro Takeuchi, Naoto Azuma, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Kiyoshi Matsui

{"title":"Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study.","authors":"Chie Ogita, Kazuteru Noguchi, Jiro Takeuchi, Naoto Azuma, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Kiyoshi Matsui","doi":"10.1080/25785826.2024.2448912","DOIUrl":"10.1080/25785826.2024.2448912","url":null,"abstract":"Rituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients with AAV. Patients were divided into three groups based on RTX administration: continuous, induction phase-only, and maintenance phase-only groups. The continuous group had a remission maintenance rate after 48 weeks of treatment compared with the induction phase-only group (100% vs. 88.2%, p = 0.29). More patients in the continuous group received three or more RTX doses during the induction period (82.4% vs. 52.9%, p = 0.06), and this group had a lower incidence of infection (5.9% vs. 29.4%, p = 0.08). Compared with the maintenance-only group, the continuous group had a numerically higher proportion of patients in remission after 48 weeks of treatment (100% vs. 83.3%, p = 0.26) and a lower incidence of infection (5.9% vs. 50%, p = 0.04); however, the N in the maintenance phase was small and suspected to have low power. Regardless of the method of RTX administration (induction phase-only or continuous), administering RTX during the induction phase may be crucial for achieving remission.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"203-210"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0